deltatrials
Completed PHASE3 INTERVENTIONAL 1-arm NCT04201262

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Sponsor: Alexion Pharmaceuticals, Inc.

Conditions Neuromyelitis Optica Neuromyelitis Optica Spectrum Disorder
Interventions Ravulizumab
Updated 25 times since 2020 Last updated: Sep 24, 2025 Started: Dec 9, 2019 Primary completion: Mar 15, 2022 Completion: Oct 31, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04201262, this PHASE3 trial focuses on Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder and remains completed. Sponsored by Alexion Pharmaceuticals, Inc., it has been updated 25 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Mar 2022 · 10 months · monthly snapshot~Mar 2022 – ~Jul 2022 · 4 months · monthly snapshot~Jul 2022 – ~Apr 2023 · 9 months · monthly snapshot~Apr 2023 – ~Sep 2023 · 5 months · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Feb 2025 · 3 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 8 months · monthly snapshot

Change History

25 versions recorded

  1. Nov 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE3

  3. Feb 2025 — Sep 2025 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Nov 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 20 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Apr 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

  6. Mar 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

  7. May 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  8. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

  9. Feb 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  10. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  11. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  12. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  13. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  14. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  15. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  16. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  17. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  18. Apr 2020 — Jun 2020 [monthly]

    Recruiting PHASE3

  19. Feb 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

  20. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alexion Pharmaceuticals, Inc.
Data source: Alexion Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus, Denmark , Aurora, United States , Barcelona, Spain , Berlin, Germany , Boston, United States , Burnaby, Canada , Camperdown, Australia , Cefalù, Italy , Chiba, Japan , Cincinnati, United States and 27 more locations